Lucid Diagnostics Inc. - Common Stock (LUCD)
0.9798
-0.0002 (-0.02%)
NASDAQ· Last Trade: Aug 13th, 3:22 PM EDT
Detailed Quote
| Previous Close | 0.9800 |
|---|---|
| Open | 0.9800 |
| Bid | 0.9734 |
| Ask | 0.9799 |
| Day's Range | 0.9653 - 1.015 |
| 52 Week Range | 0.8605 - 1.629 |
| Volume | 821,936 |
| Market Cap | 134.73M |
| PE Ratio (TTM) | -1.113 |
| EPS (TTM) | -0.9 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,463,676 |
Chart
About Lucid Diagnostics Inc. - Common Stock (LUCD)
Lucid Diagnostics Inc is a technology company focused on advancing the field of diagnostic solutions in healthcare. It specializes in the development and commercialization of innovative medical devices and diagnostic tests aimed at improving patient outcomes and streamlining the detection of various diseases, particularly in the gastrointestinal sector. The company is committed to creating impactful tools that enhance the efficiency and accuracy of disease diagnosis, thereby supporting healthcare professionals in delivering better care to patients. Its portfolio includes both proprietary technologies and collaborations aimed at bringing cutting-edge diagnostics to the market. Read More
News & Press Releases
Lucid Diagnostics (NASDAQ:LUCD) reported second-quarter revenue of $1.5 million on 2,770 EsoGuard tests, as the company continued to target quarterly test volume of roughly 2,500 to 3,000 tests while awaiting a Medicare draft local coverage determination, or LCD.
Chief Executive Officer Dr. Lishan
Via MarketBeat · August 13, 2026
Lucid Diagnostics (NASDAQ:LUCD) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
Via Benzinga · August 13, 2026
PAVmed (PAVM) Q4 2025 Earnings Transcript
Via The Motley Fool · May 15, 2026
LUCD Q1 2026 Earnings Transcript
Via The Motley Fool · May 14, 2026
Lucid Diagnostics (NASDAQ:LUCD) reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination and is expanding efforts with the Department of Veterans Affairs, commercial payers and health sys
Via MarketBeat · May 14, 2026

Lucid Diagnostics (LUCD) Earnings Transcript
Via The Motley Fool · March 26, 2026
The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.
Via Stocktwits · January 21, 2026
Via Benzinga · September 10, 2025
Via Benzinga · September 10, 2025
Via Benzinga · September 9, 2025
Lucid Diagnostics (LUCD) Q2 2025 results: Revenue $1.16M, EPS -$0.10, beating estimates. Processed 2,756 EsoGuard tests, maintains $30M+ cash. Stock up 2.26% pre-market.
Via Chartmill · August 13, 2025

Via Benzinga · June 2, 2025

Via Benzinga · June 2, 2025
A Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes with expected Medicare reimbursement approval.
Via Benzinga · April 11, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · April 10, 2025
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · April 10, 2025
Via Benzinga · April 10, 2025
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · April 10, 2025
